A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.
The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager.
Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
William Blair notes that the case report demonstrates that Blincyto effectively treated a patient with severe systemic sclerosis, leading to rapid B-cell depletion and symptom improvement without increasing infection risk or affecting antibody levels.
This suggests the potential for ...Full story available on Benzinga.com
Related tickers: AMGN, CGEM.
Read Full Article